+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Glucagon-Like Peptide-1 Receptor Imaging with [Lys (40) (Ahx-HYNIC- (99 m) Tc/EDDA)NH 2 ]-Exendin-4 for the Diagnosis of Recurrence or Dissemination of Medullary Thyroid Cancer: A Preliminary Report



Glucagon-Like Peptide-1 Receptor Imaging with [Lys (40) (Ahx-HYNIC- (99 m) Tc/EDDA)NH 2 ]-Exendin-4 for the Diagnosis of Recurrence or Dissemination of Medullary Thyroid Cancer: A Preliminary Report



International Journal of Endocrinology 2013: 384508-384508



Introduction. Epidemiological studies on medullary thyroid cancer (MTC) have shown that neither a change in stage at diagnosis nor improvement in survival has occurred during the past 30 years. In patients with detectable serum calcitonin and no clinically apparent disease, a careful search for local recurrence, and nodal or distant metastases, should be performed. Conventional imaging modalities will not show any disease until basal serum calcitonin is at least 150 pg/mL. The objective of the study was to present the first experience with labelled glucagon-like peptide-1 (GLP-1) analogue [Lys(40)(Ahx-HYNIC-(99m)Tc/EDDA)NH2]-exendin-4 in the visualisation of MTC in humans. Material and Method. Four patients aged 22-74 years (two with sporadic and two with MEN2 syndrome-related disseminated MTC) were enrolled in the study. In all patients, GLP-1 receptor imaging was performed. Results. High-quality images were obtained in all patients. All previously known MTC lesions have been confirmed in GLP-1 scintigraphy. Moreover, one additional liver lesion was detected in sporadic MTC male patient. Conclusions. GLP-1 receptor imaging with [Lys(40)(Ahx-HYNIC-(99m)Tc/EDDA)NH2]-exendin-4 is able to detect MTC lesions. GLP-1 scintigraphy can serve as a confirmatory test in MTC patients, in whom other imaging procedures are inconsistent.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 053422938

Download citation: RISBibTeXText

PMID: 23606839

DOI: 10.1155/2013/384508


Related references

Glucagon-Like Peptide-1 Receptor Imaging with Lys40Ahx-HYNIC-99mTc/EDDANH2-Exendin-4 for the Diagnosis of Recurrence or Dissemination of Medullary Thyroid Cancer A Preliminary Report. International Journal of Endocrinology 2013: 1-6, 2013

Glucagon-like peptide-1 receptor imaging with [Lys40(Ahx-HYNIC- 99mTc/EDDA)NH2]-exendin-4 for the detection of insulinoma. European Journal of Nuclear Medicine and Molecular Imaging 40(4): 524-531, 2013

Two peptide receptor ligands (99m)Tc-EDDA/HYNIC-Tyr(3)-octreotide and (99m)Tc-EDDA/HYNIC-(D)Glu-octagastrin for scintigraphy of medullary thyroid carcinoma. Cancer BioTherapy and Radiopharmaceuticals 22(5): 613-628, 2007

Glucagon-like peptide-1 receptor imaging with Lys40Ahx-HYNIC-99mTc/EDDANH2-exendin-4 for the detection of insulinoma. 2013

A freeze-dried kit formulation for the preparation of Lys(27)(99mTc-EDDA/HYNIC)-Exendin(9-39)/99mTc-EDDA/HYNIC-Tyr3-Octreotide to detect benign and malignant insulinomas. Nuclear Medicine and Biology 42(12): 911-916, 2015

Synthesis, development and preclinical comparison of two new peptide based freeze-dried kit formulation Tc-99m-EDDA-Tricine-HYNIC-TOC and Tc-99m-EDDA-Tricine-HYNIC-TATE for somatostatin receptor positive tumor scintigraphy. Daru 14(4): 183-189, 2006

Somatostatin receptor scintigraphy using 99mTc-EDDA/HYNIC-TOC in patients with medullary thyroid carcinoma. European Journal of Nuclear Medicine and Molecular Imaging 34(10): 1635-1645, 2007

Somatostatin receptor scintigraphy using 99mTc-EDDA/HYNIC-TOC for recurrent and metastatic non-medullary thyroid cancer in patients with negative radioiodine scintigraphy. Journal of Nuclear Medicine 44(5 Suppl.): 386P, 2003

99mTc-EDDA/HYNIC-TOC in the management of medullary thyroid carcinoma. Cancer Biotherapy & Radiopharmaceuticals 19(2): 211-217, 2004

Preparation and evaluation of 99mTc-EDDA/HYNIC-[Lys 3]-bombesin for imaging gastrin-releasing peptide receptor-positive tumours. Nuclear Medicine Communications 27(4): 371-376, 2006

The major determinant of exendin-4/glucagon-like peptide 1 differential affinity at the rat glucagon-like peptide 1 receptor N-terminal domain is a hydrogen bond from SER-32 of exendin-4. British Journal of Pharmacology 160(8): 1973-1984, 2010

Preliminary application of micro-SPECT/CT imaging by 99m Tc-tricine-EDDA-HYNIC-c-Met for non-small-cell lung cancer. Chemical Biology and Drug Design 93(4): 447-453, 2019

99m Tc-HYNIC-(tricine/EDDA)-FROP peptide for MCF-7 breast tumor targeting and imaging. Journal of Biomedical Science 25(1): 17, 2018

99mTc-EDDA/HYNIC-TOC in the diagnosis of differentiated thyroid carcinoma refractory to radioiodine treatment. Nuclear Medicine Review. Central and Eastern Europe 19(2): 67-73, 2016

Non-invasive glucagon-like peptide-1 receptor imaging in pancreas with (18)F-Al labeled Cys(39)-exendin-4. Biochemical and Biophysical Research Communications 471(1): 47-51, 2016